Share Your Experience with Neuroendocrine Tumor Treatment

We’re excited to share with you a new study for patients with neuroendocrine tumors (NETs) who have switched from monthly Sandostatin LAR® (octreotide) to Somatuline® Depot (lanreotide) injections within the past 12 months. If you are a NET patient 21 years or older, who lives in the United States, we invite you to see if you are eligible to participate. Please check this out today because there are a limited number of individuals who can participate in the study. Immediately upon completion of the interview, in appreciation for your time, a Visa gift card in the amount of $100 will be mailed to you.

NET Treatment Research Study

Your voice makes a difference for NET patients – thanks so much for your interest in this study! For more information and to see if you are eligible for the study, click here:

Print Friendly, PDF & Email